A Phase 1/2 Study of Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines
Latest Information Update: 24 Apr 2024
At a glance
- Drugs Elasomeran (Primary) ; NVX CoV 2373 (Primary) ; Ad26.COV2 S; Tozinameran
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- 01 Sep 2023 Status changed from active, no longer recruiting to completed.
- 20 Jul 2023 Planned End Date changed from 2 Jul 2024 to 16 Jun 2024.
- 20 Jul 2023 Planned primary completion date changed from 2 Jul 2024 to 16 Jun 2024.